Loading clinical trials...
Loading clinical trials...
Phase I Trial to Determine Optimal Phase II Dose of the Oral Dual CAIX Inhibitor/ Radiosensitizer
Conditions
Interventions
DTP348
Locations
1
Netherlands
Maastro Clinic
Maastricht, Limburg, Netherlands
Start Date
March 1, 2017
Primary Completion Date
June 1, 2017
Completion Date
July 1, 2017
Last Updated
March 3, 2017
NCT06898450
NCT06658951
NCT05719558
NCT05101070
NCT06307795
NCT06716138
Lead Sponsor
Maastricht Radiation Oncology
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions